Martin Tolar

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 4 papers. Top paper: “APOLLOE4 Phase 3 study of oral ALZ‐801/valiltramiprosate in APOE ε4/ε4 homozygotes with early Alzheimer's disease: Trial design and baseline characteristics”.

APOLLOE4 Phase 3 study of oral ALZ‐801/valiltramiprosate in APOE ε4/ε4 homozygotes with early Alzheimer's disease: Trial design and baseline characteristics

Alzheimer s & Dementia Translational Research & Clinical Interventions(2024)10.1002/trc2.12498

N/A

0.470DataRank · unranked

22 citations

Anton P. Porsteinsson, Marwan Sabbagh, David Watson, Aidan Power, Earvin Liang +8 more

Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer’s Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 Trial

Drugs(2025)10.1007/s40265-025-02250-5

N/A

0.457DataRank · unranked

20 citations

Aidan Power, David Watson, Anton Porsteinsson, Marwan Sabbagh, Emer MacSweeney +15 more

Hippocampal Atrophy on Magnetic Resonance Imaging as a Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Symptomatic Alzheimer’s Disease: Synthesis of Evidence from Observational and Interventional Trials

CNS Drugs(2026)10.1007/s40263-025-01251-y

N/A

0.208DataRank · unranked

3 citations

P. Murali Doraiswamy, John A. Hey, Duygu Tosun, Frederik Barkhof, Jerome Barakos +24 more

Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval

Alzheimer s Research & Therapy(2020)10.1186/s13195-020-00663-w

N/A

0DataRank · unranked

357 citations

Susan Abushakra, John A. Hey, Anton P. Porsteinsson, Marwan N. Sabbagh, Martin Tolar